A Prospective, Non-interventional, Registry Study of Patients Initiating a Course of DrugTherapy for Overactive Bladder (OAB)
Phase of Trial: Phase IV
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms PERSPECTIVE
- Sponsors Astellas Pharma
- 17 Oct 2017 Status changed from active, no longer recruiting to completed.
- 29 Jun 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.
- 29 Jun 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017.